Ariana Pharma news
- Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
- CY6463 favorable tolerability and safety profile was confirmed
Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results from a post hoc analysis of CY6463 first-in-human studies at the 2
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study.
Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in collaboration with Anavex Life Sciences Corp. (Nasdaq: AVXL), a
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth.
Marion and Bertrand will be bringin
Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have the potential to expand personalized cancer treatment options for patients with advanced & refractory diseases.
Focusing on a cohort of
Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference.
MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant, corresponding to a relat
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma (Cambridge, MA and Paris, France) today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment.
Ariana Pharma’s propriet
Ariana, a leading eXplainable Artificial Intelligence (AI) drug development company, is delighted to announce the appointment of Dr. Hichem Chakroun as Executive VP, Clinical Development. As EVP, Hichem will apply his industry expertise and experience to help accelerate the strategy of Ariana in the clinical trials setting.
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas and
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies.
The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-imm